Deciphering the Clinical Presentations, Pathogenesis, and Treatment of the Idiopathic Inflammatory Myopathies
- 12 January 2011
- journal article
- case report
- Published by American Medical Association (AMA) in JAMA
- Vol. 305 (2) , 183-190
Abstract
The idiopathic inflammatory myopathies or myositis syndromes (the most common forms are polymyositis, dermatomyositis, and inclusion body myositis) are systemic autoimmune diseases defined by chronic muscle weakness and inflammation of unknown etiology and result in significant morbidity and mortality. Research suggests that categorizing heterogeneous myositis syndromes into mutually exclusive and stable phenotypes by using clinical and immune response features is useful for predicting clinical signs and symptoms, associated genetic and environmental risk factors, and responses to therapy and prognosis. Knowledge of myositis phenotypes should enhance clinicians' ability to recognize and manage these rare disorders.Keywords
This publication has 48 references indexed in Scilit:
- Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumoniaRespiratory Medicine, 2009
- Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage indexArthritis & Rheumatism, 2009
- Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatmentBest Practice & Research Clinical Rheumatology, 2009
- Genetic risk and protective factors for the idiopathic inflammatory myopathiesCurrent Rheumatology Reports, 2009
- Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti–Mi‐2 autoantibodies in womenArthritis & Rheumatism, 2009
- RNA helicase encoded by melanoma differentiation–associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung diseaseArthritis & Rheumatism, 2009
- Defining cancer risk in dermatomyositis. Part IClinical and Experimental Dermatology, 2009
- Treatment of the inflammatory myopathies: update and practical recommendationsExpert Opinion on Pharmacotherapy, 2009
- Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositisBrain, 2009
- Immunoprecipitation-Western Blot for Proteins of Low Abundance2009